Search results for " middle"

showing 10 items of 1097 documents

Lower and Middle Cambrian brachiopods from the Iberian Chains and Sierra Morena (Spain)

2021

Brachiopods from the Lower and Middle Cambrian of the Iberian Chains and Sierra Morena are described. The following taxa occur in the Iberian Chains: "Lingulella" sp., Redlichella cf. bohemica (Barrande), Dictyonina radioplicata sp. n., Micromitra sp., Trematobolus simplex (Vogel), Trematobolus borobiensis sp. n. and Jamesella sp. The taxa "Lingulella" sp. and Sibiria? sp. are reported from the Lower Cambrian of Sierra Morena. Brachiopods constitute several distinct associations: the relatively shallow water Trematobolus assemblage near the Lower-Middle Cambrian boundary interval is followed by the deeper Dictyonina­Redlichella assemblage. The alternation of these assemblages permit us to i…

LingulellaPaleontologyWaves and shallow waterTaxonbiologyMicromitraPaleontologyAssemblage (archaeology)biology.organism_classificationbrachiopoda lower cambrian middle cambrian spain.QE701-760GeologySea levelSpanish Journal of Palaeontology
researchProduct

Joan Roís de Corella, La Istòria de Leànder y Hero: edizione critica con studio introduttivo

2018

This contribution is a further partial anticipation of the critical edition of the mythological faules of Joan Roís de Corella (15th century) for Barcino (ENC), after that appeared in Magnificat, vol.3, 2016. It focuses on one of the author's most mature and significant faules, as well as one of the most prestigious testimonies both of the presence of the myth of Ero and Leandro in the Iberian 15th century, and of the peninsular reception of the Heroides. The paper consists of two parts. In the first part, Introduction, the current situation of the studies related to the Istòria is first summarized. Next, the analysis of the literary memory that supports the discursive construction of the f…

LiteratureUNESCO::CIENCIAS DE LAS ARTES Y LAS LETRASHistoryLiterature and Literary Theorybusiness.industrymedia_common.quotation_subjectJoan Roís de CorellaMedieval Catalan literatureMythologyArtCritical editioncritical editionMedieval Catalan literature; Joan Roís de Corella; mythological narratives; Leander and Hero; critical edition; medieval Ovid.Ovid in the Middle Ages.:CIENCIAS DE LAS ARTES Y LAS LETRAS [UNESCO]mythological narrativeHEROInventionEro and LeandrobusinessMirroringmedia_common
researchProduct

Gender differences in chronic HBsAg carriers in Italy: Evidence for the independent role of male sex in severity of liver disease

2015

It has been shown that sexual hormones have an opposite effect on hepatic fibrosis progression and hepatocellular carcinoma development. Sex differences among 2,762 chronic HBsAg carriers consecutively referring Italian hospitals in 2001 and in 2007 have been evaluated, particularly focusing on the role of gender on severity of liver disease. The overall sex ratio (males/females) was 2.6. Females were more likely born abroad and new diagnosis cases; but less likely HIV coinfected. No sex difference was observed regarding coinfection with other hepatitis viruses. The sex ratio linearly increased with increasing severity of liver disease, being 1.3 in normal ALT, 2.8 in chronic hepatitis, 3.6…

Liver CirrhosisAdultMaleChronic HBsAg carriers; Cirrhosis; Hepatocellular carcinoma; Sex differences; Adult; Aged; Carcinoma Hepatocellular; Female; Hepatitis B Surface Antigens; Hepatitis B Chronic; Humans; Italy; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Sex Factors; Virology; Infectious DiseasesCarcinoma HepatocellularHepatocellular carcinomaLiver CirrhosiHepatitis B Surface AntigenChronic HBsAg carriersHepatitis B ChronicSex FactorsVirologySex differencesHumansChronicAgedChronic HBsAg carrierHepatitis B Surface AntigensCirrhosiCarcinomaLiver NeoplasmsHepatocellularMiddle AgedHepatitis BSex differenceInfectious DiseasesCirrhosisItalyLiverLiver NeoplasmFemaleHuman
researchProduct

Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies

2017

Progression of liver fibrosis in patients with hemoglobinopathies is strongly related to the severity of iron overload and the presence of chronic hepatitis C virus (HCV) infection. Effective iron chelation therapy and HCV infection eradication may prevent liver complications. The European Association for the Study of the Liver guidelines recommend interferon-free regimens for the treatment of HCV infection in patients with hemoglobinopathies. However, data regarding the use of direct-acting antiviral drugs (DAAs) in this patient population are few. This observational study evaluated the safety and efficacy of therapy with DAAs in an Italian cohort of patients with hemoglobinopathies, chron…

Liver CirrhosisAdultMalemedicine.medical_specialtyIron OverloadThalassemiaHepatitis C virusLiver CirrhosiIron Chelating Agentsmedicine.disease_causeAntiviral AgentsGastroenterologyVirus03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicinechronic hepatitis CHumansHematology hemoglobinopathies chronic hepatitis C direct antiviral agentsChelation therapyChronicAntiviral AgentSettore MED/12 - GastroenterologiaHematologybusiness.industrydirect antiviral agentsAdult; Antiviral Agents; Female; Hemoglobinopathies; Hepatitis C Chronic; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Male; Middle Aged; Treatment Outcome; HematologyHepatitis CHematologyHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CHemoglobinopathiesHemoglobinopathieIron Chelating AgentTreatment Outcome030220 oncology & carcinogenesisImmunologyCohort030211 gastroenterology & hepatologyFemalebusinessHuman
researchProduct

Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

2017

Abstract Hepatitis C virus (HCV) infection remains one of the main causes of chronic liver disease worldwide. The advent of direct-acting antivirals (DAAs) has significantly improved the course of patients with chronic HCV infection (CHC), due to the ability of these drugs to achieve high rates of sustained virological response (SVR). These exceedingly high rates of SVR and the excellent safety data have been confirmed in real life practice. Evolving guidelines have been issued by national and international scientific societies in accordance with the progression of clinical knowledge and the availability of new DAAs. These recommendations, however, may not be applied universally because of …

Liver CirrhosisDirect-acting antiviral agentFibrosiHepacivirusChronic liver diseasemedicine.disease_causeClinical knowledgeVirological response0302 clinical medicine80 and over030212 general & internal medicineChronicAntiviral treatment; Cirrhosis; Direct-acting antiviral agents; Hepatitis C; RAV; Treatment failureAged 80 and overGastroenterologyAntiviral treatment; Cirrhosis; Direct-acting antiviral agents; Hepatitis C; RAV; Treatment failure; Hepatology; GastroenterologyHepatitis CMiddle AgedViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CCirrhosisItalyLiverCombination030211 gastroenterology & hepatologyDrug Therapy CombinationHumanAdultmedicine.medical_specialtyConsensusHepatitis C virusLiver CirrhosiConsensuAntiviral AgentsUnmet needs03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansIntensive care medicineAgedAntiviral AgentHepaciviruCirrhosiHepatologybusiness.industryHepatologyHepatitis C Chronicmedicine.diseaseVirologyFibrosisAntiviral treatmentTreatment failurePosition paperAntiviral treatment; Cirrhosis; Direct-acting antiviral agents; Hepatitis C; RAV; Treatment failure; Adult; Aged; Aged 80 and over; Antiviral Agents; Consensus; Drug Therapy Combination; Fibrosis; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Liver; Liver Cirrhosis; Middle Aged; Viral Load; Young AdultDirect-acting antiviral agentsRAVbusiness
researchProduct

Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.

2022

Background & Aim: Non-alcoholic fatty liver disease (NAFLD), and especially fibrotic non-alcoholic steatohepatitis, is associated with high risks of liver-related events (LRE) and extrahepatic events (EHE). We evaluated the competitive risk occurrence of LRE and EHE in a large cohort of biopsy-proven NAFLD stratified according to baseline severity of fibrosis. Methods: Two thousand one hundred thirty-five patients with biopsy-proven NAFLD were enrolled. Observed cumulative incidence functions (CIFs) were used to evaluate the risk of LRE and EHE; cause-specific Cox model and predicted CIFs were fitted to identify predictors of LRE and EHE. A replication cohort of NAFLD patients with live…

Liver CirrhosisHepatologyBiopsyGastroenterologyNASHMiddle AgedFibrosisBiopsy; Fibrosis; Humans; Liver; Liver Cirrhosis; Middle Aged; Retrospective Studies; Elasticity Imaging Techniques; Non-alcoholic Fatty Liver DiseaseLiverNon-alcoholic Fatty Liver DiseaseElasticity Imaging TechniquesHumansPharmacology (medical)610 Medicine & healthRetrospective StudiesAlimentary pharmacologytherapeuticsREFERENCES
researchProduct

MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease

2015

Background & Aim Homozygosity for a common non-coding rs4374383 G>A polymorphism in MERTK (myeloid-epithelial-reproductive tyrosine kinase) has been associated with the protection against fibrosis progression in chronic hepatitis C. The main study objective was to assess whether MERTK AA genotype influences liver fibrosis, and secondarily MERTK expression in patients with non-alcoholic fatty liver disease (NAFLD). We also investigated whether MERTK is expressed in human hepatic stellate cells (HSC) and in murine models of fibrogenesis. Methods We considered 533 consecutive patients who underwent liver biopsy for suspected non-alcoholic steatohepatitis (NASH) without severe obesity from two …

Liver CirrhosisMale0301 basic medicineMessengerMice0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInbred BALB CCells CulturedMice Inbred BALB CCulturedmedicine.diagnostic_testMedicine (all)Fatty liverNASHMiddle AgedLiver biopsyFemale030211 gastroenterology & hepatologyAdultmedicine.medical_specialtyMERTKCellsBiology03 medical and health sciencesGeneticProto-Oncogene ProteinsInternal medicinemedicineAnimalsHumansFibrosis; MERTK; NASH; Adult; Animals; Cells Cultured; Female; Humans; Liver Cirrhosis; Male; Mice Inbred BALB C; Middle Aged; Non-alcoholic Fatty Liver Disease; Proto-Oncogene Proteins; RNA Messenger; Receptor Protein-Tyrosine Kinases; Polymorphism Genetic; Medicine (all); HepatologyRNA MessengerPolymorphismPolymorphism Geneticc-Mer Tyrosine KinaseHepatologyGAS6Receptor Protein-Tyrosine Kinasesnafld fibrosis mertkMERTKHepatologymedicine.diseaseFibrosis030104 developmental biologyImmunologyHepatic stellate cellRNASteatohepatitisJournal of Hepatology
researchProduct

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

2007

The effect of achieving a sustained virological response (SVR) following interferon-α (IFNα) treatment on the clinical outcomes of patients with HCV-related cirrhosis is unknown. In an attempt to assess the risk of liver-related complications, HCC and liver-related mortality in patients with cirrhosis according to the response to IFNα treatment, a retrospective database was developed including all consecutive patients with HCV-related, histologically proven cirrhosis treated with IFNα monotherapy between January 1992 and December 1997. SVR was an undetectable serum HCV-RNA by PCR 24 weeks after IFNα discontinuation. HCC was assessed by ultrasound every 6 months. Independent predictors of al…

Liver CirrhosisMaleANTIVIRAL TREATMENTMultivariate analysisCirrhosisHepacivirusdrug therapy/mortality/virologyGastroenterologyCohort StudiesINTERFERON; HEPATITIS C; CIRRHOSIS; CHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; SUSTAINED VIROLOGICAL RESPONSE; Liver cirrhosis.MedicinegeneticsLongitudinal StudiesViralCIRRHOSISHazard ratiovirus diseasesHepatitis CAdult Antiviral Agents; therapeutic use Cohort Studies Female Hepacivirus; genetics Hepatitis C; blood/complications/drug therapy/mortality Humans Interferon-alpha; therapeutic use Liver Cirrhosis; drug therapy/mortality/virology Longitudinal Studies Male Middle Aged Multivariate Analysis RNA; Viral; blood Retrospective Studies Survival Analysis Treatment OutcomeMiddle AgedLiver cirrhosis.Treatment OutcomeSUSTAINED VIROLOGICAL RESPONSEHEPATITIS CLiver Cirrhosis/drug therapy Liver Cirrhosis/virologyRNA ViralFemaleAdultINTERFERONmedicine.medical_specialtyCHRONIC HEPATITIS CAntiviral AgentsbloodInternal medicineHumansRetrospective StudiesSustained virological response interferon-alpha HCV-related cirrhosis:Hepatologybusiness.industryProportional hazards modelInterferon-alphaRetrospective cohort studyblood/complications/drug therapy/mortalityHepatologymedicine.diseaseSurvival Analysisdigestive system diseasesDiscontinuationSurgerytherapeutic useMultivariate AnalysisRNAbusiness
researchProduct

Characteristics and Changes over Time of Alcohol-Related Chronic Liver Diseases in Italy

2018

Introduction. To evaluate the characteristics of alcohol-related chronic liver disease (CLD) in Italy and their potential changes over time. Patients and Methods. Subjects with CLD were enrolled in two national surveys performed in 2001 and in 2014 in Italy. The two surveys prospectively recruited patients aged ≥ 18 years referring to more than 80 Italian liver units scattered all over the country using similar clinical approach, analytical methods, and threshold of risky alcohol intake definition (≥ 3 units/day in men and ≥ 2 units/day in women). Results. Out of 12,256 enrolled subjects, 2,717 (22.2%) reported a risky alcohol intake. Of them, anti-HCV positive was observed in 48.3% of subj…

Liver CirrhosisMaleCirrhosisChronic liver diseaseHealth Risk BehaviorsHealth Risk BehaviorLiver disease0302 clinical medicineStage (cooking)ChronicLiver DiseasesGastroenterologyGeneral MedicineHepatitis CHealth SurveyMiddle AgedAlcoholicHepatitis CAlcoholismItaly030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleSex ratioAdult; Aged; Alcohol Drinking; Alcoholism; Chronic Disease; Female; Health Risk Behaviors; Health Surveys; Hepatitis C Antibodies; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Liver Diseases Alcoholic; Male; Middle AgedResearch ArticleHumanAdultmedicine.medical_specialtyArticle SubjectAlcohol DrinkingLiver Cirrhosi03 medical and health sciencesInternal medicinemedicineHumanslcsh:RC799-869Liver Diseases AlcoholicAgedHepatologybusiness.industryHepatologyHepatitis C AntibodiesHepatitis C Chronicmedicine.diseaseHealth SurveysAgeingChronic Diseaselcsh:Diseases of the digestive system. GastroenterologybusinessHepatitis C Antibodie
researchProduct

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data

2004

Multicenter randomized trials have shown that once-weekly pegylated interferon (peginterferon) alfa-2a is more efficacious than conventional interferon alfa-2a (IFN) in patients with chronic hepatitis C. We performed a meta-analysis of 1,013 previously untreated patients (from 3 randomized trials) with pretreatment and post-treatment liver biopsies to assess the differences between peginterferon alfa-2a and IFN in terms of their effects on liver histology. Reported values were standardized mean differences (SMD) between patients receiving peginterferon alfa-2a and those receiving IFN (post-treatment value minus baseline value for each group). We used a random-effects model to quantify the a…

Liver CirrhosisMaleCirrhosisFibrosiFemalGastroenterologyPolyethylene Glycolslaw.inventionRandomized controlled trialFibrosislawPegylated interferonChronicInterferon Alfa-2aInterferon Alfa-2bvirus diseasesHepatitis CMiddle AgedAdult; Antiviral Agents; Femal; Hepatitis C; Chronic; Humans; Interferon Alfa-2a; Interferon Alfa-2b; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Treatment Outcome; eHepatitis CRecombinant ProteinseTreatment OutcomeLiverPredictive value of testsFemalePeginterferon alfa-2amedicine.drugAdultmedicine.medical_specialtyEfficacypegylated interferon-alpha-2bBody-mass indexInterferon alpha-2Antiviral AgentsPredictive Value of TestsInternal medicinemedicineHumansInterferon-alpha therapySteatosiHepatologybusiness.industryInterferon-alphaHepatitis C ChronicHepatologymedicine.diseaseImmunologybusinessPredictor
researchProduct